Cutaneous adverse events caused by immune checkpoint inhibitors

Journal of the American Academy of Dermatology, Journal Year: 2021, Volume and Issue: 85(4), P. 956 - 966

Published: July 28, 2021

Language: Английский

---

Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors

Journal of Veterinary Science, Journal Year: 2024, Volume and Issue: 25(1)

Published: Jan. 1, 2024

The anti-programmed death 1 (PD-1) antibody has led to durable clinical responses in a wide variety of human tumors. We have previously developed the caninized anti-canine PD-1 (ca-4F12-E6) and evaluated its therapeutic properties dogs with advance-staged oral malignant melanoma (OMM), however, their effects on other types canine tumors remain unclear.

Language: Английский

---

A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology

Seminars in Arthritis and Rheumatism, Journal Year: 2024, Volume and Issue: 66, P. 152440 - 152440

Published: March 27, 2024

Vasculitis as an immune-related adverse event (irAE) from checkpoint inhibitor therapy (ICI) to treat cancer is a rare clinical event, and little known regarding its nosology, manifestations, or response treatment outcomes. To address these gaps, we used the Preferred Reporting Items for Systemic Reviews Meta-Analyses Extension Scoping (PRISMA-ScR) framework further define this complication. Two independent PUBMED searches in September November of 2022 revealed 127 publications with 37 excluded title by relevance, 43 article type, 23 due lack biopsy results, negative vasculitis. Twenty-nine documented cases 24 were included final analysis. Basic demographics, ICI details, timing onset vasculitis symptoms, irAE outcomes collected. The vasculitides classified using ACR/EULAR Classification Criteria well 2012 Revised Chapel-Hill Nomenclature. Adaptations Naidoo et al 2023 [1] consensus definitions irAEs efforts made classify steroid-responsive versus unresponsive irAEs. Of 29 reviewed, average age patients was 62.1 ± 11.0, composed 58.6% (n=17) male 41.3% (n=12) female. Prominent types lung (41.4%; n=12), melanoma renal (10.3%; n=3), majority being stage 4 (75.9%, n=22) 3 (10.3%, n=3). Only 8 met criteria, Nomenclature, approximately third small-vessel (31.0%; n=9) n=4 positive ANCA. Most biopsies taken skin (37.9%, n=11) kidney (24.1%, n=7). Patients either treated single (65.5%, n=19), dual (17.2%; n=5), sequential n=5) regimen which anti-PD-1 all but one case, mean 8.7 10.5 cycles received. Mean time symptoms start 7.2 7.8 months, 55.2% occurring >3 months since initial immunotherapy. glucocorticoids 96% immunotherapy often discontinued (44.8%; n=13). Clinical improvement 86.2% (n=25). Data missing terms fate (34.5%; n=10) tumor n=12). Cancer progressed 20.7% (n=6), stable 34.5% (n=10) cases, 6 died all-causes. appears clinically heterogeneous rare. Among reported adequate documentation, delayed following initiation Outcomes ICI-vasculitis generally favorable, responding withdrawal. There urgent need more standardized reporting such clarify risks, classification, relationship

Language: Английский

---

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors

International Journal of Molecular Sciences, Journal Year: 2020, Volume and Issue: 21(9), P. 3389 - 3389

Published: May 11, 2020

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that activate the immune system, aiming at enhancing antitumor immunity. Their clinical efficacy is well-documented, but side effects associated with their use still under investigation. These drugs cause several immune-related adverse events (ir-AEs), some of which stand within field rheumatology. Herein, we present a literature review performed in an effort to evaluate all publicly available data regarding rheumatic manifestations ICIs. The most common musculoskeletal ir-AEs inflammatory arthritis, polymyalgia rheumatica and myositis. Non-musculoskeletal less frequent, prominent being sicca, vasculitides sarcoidosis. Cases systemic lupus erythematosus or scleroderma extremely rare. majority mild/moderate severity can be managed steroids no need for ICI discontinuation. In severe cases, more intense immunosuppressive therapy permanent discontinuation may employed. Oncologists should periodically screen patients receiving ICIs new-onset complaints seek rheumatology consultation cases persisting symptoms.

Language: Английский

---

Eosinophilic granulomatosis with polyangiitis: Cutaneous clinical and histopathologic differential diagnosis

Journal of Cutaneous Pathology, Journal Year: 2021, Volume and Issue: 48(11), P. 1379 - 1386

Published: May 21, 2021

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, but severe systemic vasculitis that can affect skin and other organ systems. Diagnostic criteria have evolved, many attempts been made to classify the vasculitides based on clinical and/or histopathologic features, an aim develop standardized criteria. According EGPA Consensus Task Force recommendations, syndrome of asthma, eosinophilia, pulmonary infiltrates, extrapulmonary (such as cutaneous involvement purpura). Histopathologic evidence in may be associated eosinophilic infiltration perivascular granulomatous inflammation. We review clinicopathologic this enigmatic vasculopathy.

Language: Английский

---

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

Frontiers in Medicine, Journal Year: 2021, Volume and Issue: 8

Published: Nov. 4, 2021

Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers dramatically decreased mortality. However, with ICIs is directly associated immune-related adverse events (irAEs) because inflammation in off-target organs autoimmunity resulting from non-specific immune activation. These irAEs cause rheumatic diseases manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca Sjogen's syndrome, systemic lupus erythematosus. Early diagnosis these will improve outcomes quality life for patients. The induced by requires multidisciplinary cooperation among physicians. Furthermore, underlying mechanisms are not fully understood it difficult to predict evaluate side effects precisely. In this review, we summarize available studies findings about irAEs, focusing mainly on clinical manifestations, epidemiology, possible mechanisms, guiding principles treating irAEs.

Language: Английский

---

Immune checkpoint molecule expression is altered in the skin and peripheral blood in vasculitis

Scientific Reports, Journal Year: 2021, Volume and Issue: 11(1)

Published: Oct. 8, 2021

Abstract Dysfunction of immunoinhibitory signals and persistent T cell activation reportedly play important roles in the development vasculitis. The skin is one most accessible organs, it suitable for characterization immune signatures. However, inhibitory checkpoint molecules their relevance to vasculitis have not been studied. Here, we investigated profile peripheral blood patients with healthy donors. We found that some molecules, including programmed death 1 receptor (PD-1), were elevated T-cells systemic cutaneous In addition, death-ligand (PD-L1) expression was Histologically, PD-L1 highly expressed vessels along CD4 + CD8 T-cell infiltration Notably, plasma soluble levels increased, these correlated C-reactive protein Our findings suggest might be differentially modulated vasculitis, alteration PD-L1/PD-1 axis may associated regulation

Language: Английский

---

Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features

Human Pathology, Journal Year: 2023, Volume and Issue: 140, P. 144 - 172

Published: May 2, 2023

Language: Английский

---

Interstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab

Cutis, Journal Year: 2022, Volume and Issue: 109(3)

Published: March 1, 2022

A 61-year-old woman with a medical history of ulcerative colitis (UC) developed an erythematous, mildly pruritic, maculopapular rash that was histologically consistent reactive granulomatous dermatitis (RGD) interstitial (IGD)-type features 1 week after vedolizumab infusion.Awareness this complication is key to enhanced recognition and appropriate management as use medication becomes more prevalent.

Language: Английский

---

Eficacia y seguridad de la crioterapia con nitrógeno líquido en el tratamiento del liquen simple crónico

Dermatología Argentina, Journal Year: 2022, Volume and Issue: 28(2), P. 75 - 75

Published: June 1, 2022

El liquen simple crónico es una enfermedad cutánea acompañada de disfunción neurológica, caracterizada por liquenificación y prurito intenso. Su prevalencia mayor en las mujeres entre 30 50 años. Existen diferentes tratamientos: oclusión del área, emolientes, corticosteroides tópicos, tacrolimus pimecrolimus, fototerapia, antihistamínicos, ansiolíticos aplicación toxina botulínica, otros. La crioterapia con nitrógeno líquido inhibe terminaciones nerviosas área afectada, bloquea el círculo vicioso rascado.

---